N-Acetyl-5-HydroxytryptamineCAS# 1210-83-9 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1210-83-9 | SDF | Download SDF |
| PubChem ID | 903 | Appearance | Powder |
| Formula | C12H14N2O2 | M.Wt | 218.3 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 250 mg/mL (1145.48 mM; Need ultrasonic) | ||
| Chemical Name | N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]acetamide | ||
| SMILES | CC(=O)NCCC1=CNC2=C1C=C(C=C2)O | ||
| Standard InChIKey | MVAWJSIDNICKHF-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C12H14N2O2/c1-8(15)13-5-4-9-7-14-12-3-2-10(16)6-11(9)12/h2-3,6-7,14,16H,4-5H2,1H3,(H,13,15) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
N-Acetyl-5-Hydroxytryptamine Dilution Calculator
N-Acetyl-5-Hydroxytryptamine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.5809 mL | 22.9043 mL | 45.8085 mL | 91.617 mL | 114.5213 mL |
| 5 mM | 0.9162 mL | 4.5809 mL | 9.1617 mL | 18.3234 mL | 22.9043 mL |
| 10 mM | 0.4581 mL | 2.2904 mL | 4.5809 mL | 9.1617 mL | 11.4521 mL |
| 50 mM | 0.0916 mL | 0.4581 mL | 0.9162 mL | 1.8323 mL | 2.2904 mL |
| 100 mM | 0.0458 mL | 0.229 mL | 0.4581 mL | 0.9162 mL | 1.1452 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- ST 1936 oxalate
Catalog No.:BCC7919
CAS No.:1210-81-7
- 3'-Nitroacetophenone
Catalog No.:BCN2256
CAS No.:121-89-1
- Propyl gallate
Catalog No.:BCN8431
CAS No.:121-79-9
- 2-Amino-5-nitrothiazole
Catalog No.:BCC8538
CAS No.:121-66-4
- N-Acetylsulfanilyl chloride
Catalog No.:BCC9084
CAS No.:121-60-8
- Benzethonium Chloride
Catalog No.:BCC4635
CAS No.:121-54-0
- (-)-Terreic acid
Catalog No.:BCC7051
CAS No.:121-40-4
- Vanillic acid
Catalog No.:BCN6105
CAS No.:121-34-6
- Vanillin
Catalog No.:BCN2605
CAS No.:121-33-5
- 3-Deazaneplanocin A (DZNep) hydrochloride
Catalog No.:BCC3604
CAS No.:120964-45-6
- FPL 64176
Catalog No.:BCC7050
CAS No.:120934-96-5
- Isoliquiritin apioside
Catalog No.:BCN2914
CAS No.:120926-46-7
- JZL 195
Catalog No.:BCC7966
CAS No.:1210004-12-8
- Secretin (rat)
Catalog No.:BCC5848
CAS No.:121028-49-7
- Nelarabine
Catalog No.:BCC1072
CAS No.:121032-29-9
- IEM 1460
Catalog No.:BCC7135
CAS No.:121034-89-7
- PF-04971729
Catalog No.:BCC1852
CAS No.:1210344-57-2
- Abiesadine I
Catalog No.:BCN6104
CAS No.:1210347-50-4
- Melanotan II
Catalog No.:BCC7414
CAS No.:121062-08-6
- 3-O-trans-p-Coumaroyltormentic acid
Catalog No.:BCN4724
CAS No.:121064-78-6
- 3-O-cis-p-Coumaroyltormentic acid
Catalog No.:BCN3184
CAS No.:121072-40-0
- L-670,596
Catalog No.:BCC5857
CAS No.:121083-05-4
- EG00229
Catalog No.:BCC5376
CAS No.:1210945-69-9
- Cefprozil hydrate
Catalog No.:BCC4951
CAS No.:121123-17-9
Catecholamine and Indolamine Pathway: A Case-Control Study in Fibromyalgia.[Pubmed:30009619]
Biol Res Nurs. 2018 Oct;20(5):577-586.
OBJECTIVES: Fibromyalgia (FM) is a complex syndrome characterized by widespread pain. Its etiology is unclear, and diagnosis is difficult. The aim of this study was to assess plasma levels of monoamine neurotransmitters (catecholamines, indolamines, and intermediate metabolites) in patients with FM and healthy controls to investigate possible alterations in the metabolism of these molecules in FM. We also examined potential relationships between monoamine neurotransmitters and clinical features of FM. The predictive value of these molecules in FM was determined by receiver operating characteristic analysis. METHOD: We measured plasma catecholamines (epinephrine, norepinephrine, and dopamine), as well as indolamines and intermediary metabolites (serotonin or 5-hydroxytryptamine [5-HT], 5-hydroxyindolacetic acid [5-HIAA], 5-hydroxytryptophan [5-HTP], and N-Acetyl-5-Hydroxytryptamine [Nac-5-HT]) in 35 women with FM and 12 age-matched healthy women. RESULTS: Higher levels of norepinephrine and lower levels of dopamine, 5-HT, 5-HIAA, and 5-HTP were found in women with FM in comparison with controls. Epinephrine and Nac-5-HT levels did not differ significantly between groups. Higher norepinephrine levels were associated with worse physical health status in FM patients. Also, plasma norepinephrine levels > 694.69 pg/ml might be an accurate predictor of FM. CONCLUSIONS: These findings show evidence of the dysregulation of the catecholamine and indolamine pathway in patients with FM, which may contribute to the physiopathology of this syndrome. In addition, the determination of plasma norepinephrine levels could help in the FM diagnosis.
